Top

Abdominal Radiology

Published in:

01-04-2019 | Review

Tumor markers: myths and facts unfolded

Authors: S. C. Faria, T. Sagebiel, M. Patnana, V. Cox, C. Viswanathan, C. Lall, A. Qayyum, P. R. Bhosale

Published in: Abdominal Radiology | Issue 4/2019

Abstract

Objective

The purpose of this article is to review the most commonly used tumor markers in abdominal and pelvic tumors, describe their limitations and explain how to use them in the context of known cancer in order to optimize multidisciplinary care of oncologic patients.

Conclusion

Tumor markers are important for the diagnosis, staging, monitoring of treatment and detection of recurrence in many cancers. This knowledge is crucial in the daily interpretation of images of oncologic and non-oncologic patients. However, radiologists should also be aware of the limitations of the most commonly used tumor markers and they should not be used solely, but interpreted in conjunction with diagnostic imaging, clinical history and physical examination that will help optimize the multidisciplinary care and management of oncologic patients.

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics. CA Cancer J Clin 68(1):7–30. https://doi.org/10.3322/caac.21442 CrossRef

Duffy MJ (2013) Tumor markers in clinical practice: a review focusing on common solid cancers. Med Princ Pract 22(1):4–11. https://doi.org/10.1159/000338393 CrossRefPubMed

Holdenrieder S, Pagliaro L, Morgenstern D, Dayyani F (2016) Clinically meaningful use of blood tumor markers in oncology. Biomed Res Int 2016:9795269. https://doi.org/10.1155/2016/9795269 CrossRefPubMedPubMedCentral

Lech G, Slotwinski R, Slodkowski M, Krasnodebski IW (2016) Colorectal cancer tumour markers and biomarkers: recent therapeutic advances. World J Gastroenterol 22(5):1745–1755. https://doi.org/10.3748/wjg.v22.i5.1745 CrossRefPubMedPubMedCentral

Aslam MI, Kelkar A, Sharpe D, Jameson JS (2010) Ten years experience of managing the primary tumours in patients with stage IV colorectal cancers. Int J Surg 8(4):305–313. https://doi.org/10.1016/j.ijsu.2010.03.005 CrossRefPubMed

Goldstein MJ, Mitchell EP (2005) Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 23(4):338–351CrossRef

Iwanicki-Caron I, Di Fiore F, Roque I, et al. (2008) Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J Clin Oncol 26(22):3681–3686. https://doi.org/10.1200/jco.2007.15.0904 CrossRefPubMed

Locker GY, Hamilton S, Harris J, et al. (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24(33):5313–5327. https://doi.org/10.1200/jco.2006.08.2644 CrossRefPubMed

Wiratkapun S, Kraemer M, Seow-Choen F, Ho YH, Eu KW (2001) High preoperative serum carcinoembryonic antigen predicts metastatic recurrence in potentially curative colonic cancer: results of a five-year study. Dis Colon Rectum 44(2):231–235CrossRef

10.

Su BB, Shi H, Wan J (2012) Role of serum carcinoembryonic antigen in the detection of colorectal cancer before and after surgical resection. World J Gastroenterol 18(17):2121–2126. https://doi.org/10.3748/wjg.v18.i17.2121 CrossRefPubMedPubMedCentral

11.

Miles K, Burkill G (2007) Colorectal cancer: imaging surveillance following resection of primary tumour. Cancer Imaging 7(Spec No A):S143–S149. https://doi.org/10.1102/1470-7330.2007.9011 CrossRefPubMedPubMedCentral

12.

Scheer MG, Sloots CE, van der Wilt GJ, Ruers TJ (2008) Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol 19(11):1829–1835. https://doi.org/10.1093/annonc/mdn398 CrossRefPubMed

13.

Scheer A, Auer RA (2009) Surveillance after curative resection of colorectal cancer. Clin Colon Rectal Surg 22(4):242–250. https://doi.org/10.1055/s-0029-1242464 CrossRefPubMedPubMedCentral

14.

Duffy MJ, Lamerz R, Haglund C, et al. (2014) Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer 134(11):2513–2522. https://doi.org/10.1002/ijc.28384 CrossRefPubMed

15.

Konishi F (2002) CEA doubling time and CEA half-life in the prediction of recurrences after colorectal cancer surgery. Jpn J Clin Oncol 32(2):41–42CrossRef

16.

Connor S, Hart MG, Redhead DN, et al. (2007) Follow-up and outcomes for resection of colorectal liver metastases in Edinburgh. Eur J Surg Oncol 33(1):55–60. https://doi.org/10.1016/j.ejso.2006.09.017 CrossRefPubMed

17.

Bipat S, van Leeuwen MS, Comans EF, et al. (2005) Colorectal liver metastases: CT, MR imaging, and PET for diagnosis—meta-analysis. Radiology 237(1):123–131. https://doi.org/10.1148/radiol.2371042060 CrossRefPubMed

18.

Vreugdenburg TD, Ma N, Duncan JK, et al. (2016) Comparative diagnostic accuracy of hepatocyte-specific gadoxetic acid (Gd-EOB-DTPA) enhanced MR imaging and contrast enhanced CT for the detection of liver metastases: a systematic review and meta-analysis. Int J Colorectal Dis 31(11):1739–1749. https://doi.org/10.1007/s00384-016-2664-9 CrossRefPubMed

19.

Gade M, Kubik M, Fisker RV, Thorlacius-Ussing O, Petersen LJ (2015) Diagnostic value of (18)F-FDG PET/CT as first choice in the detection of recurrent colorectal cancer due to rising CEA. Cancer Imaging 15:11. https://doi.org/10.1186/s40644-015-0048-y CrossRefPubMedPubMedCentral

20.

Lu YY, Chen JH, Chien CR, et al. (2013) Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA: a systematic review and meta-analysis. Int J Colorectal Dis 28(8):1039–1047. https://doi.org/10.1007/s00384-013-1659-z CrossRefPubMed

21.

Mittal BR, Senthil R, Kashyap R, et al. (2011) 18F-FDG PET-CT in evaluation of postoperative colorectal cancer patients with rising CEA level. Nucl Med Commun 32(9):789–793. https://doi.org/10.1097/MNM.0b013e3283477dd7 CrossRefPubMed

22.

Selzner M, Hany TF, Wildbrett P, et al. (2004) Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 240(6):1027–1034 ((discussion 1035–1026))CrossRef

23.

de Baere T, Tselikas L, Yevich S, et al. (2017) The role of image-guided therapy in the management of colorectal cancer metastatic disease. Eur J Cancer 75:231–242. https://doi.org/10.1016/j.ejca.2017.01.010 CrossRefPubMed

24.

Attard G, Parker C, Eeles RA, et al. (2016) Prostate cancer. Lancet 387(10013):70–82. https://doi.org/10.1016/s0140-6736(14)61947-4 CrossRefPubMed

25.

Grubb RL 3rd (2018) Prostate cancer: update on early detection and new biomarkers. Mo Med 115(2):132–134PubMedPubMedCentral

26.

Schmid HP, Riesen W, Prikler L (2004) Update on screening for prostate cancer with prostate-specific antigen. Crit Rev Oncol Hematol 50(1):71–78. https://doi.org/10.1016/j.critrevonc.2003.11.001 CrossRefPubMed

27.

Adhyam M, Gupta AK (2012) A review on the clinical utility of PSA in cancer prostate. Indian J Surg Oncol 3(2):120–129. https://doi.org/10.1007/s13193-012-0142-6 CrossRefPubMedPubMedCentral

28.

Salman JW, Schoots IG, Carlsson SV, Jenster G, Roobol MJ (2015) Prostate specific antigen as a tumor marker in prostate cancer: biochemical and clinical aspects. Adv Exp Med Biol 867:93–114. https://doi.org/10.1007/978-94-017-7215-0_7 CrossRefPubMed

29.

Nordstrom T, Akre O, Aly M, Gronberg H, Eklund M (2018) Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer Prostatic Dis 21(1):57–63. https://doi.org/10.1038/s41391-017-0024-7 CrossRefPubMed

30.

Drazer MW, Huo D, Eggener SE (2015) National Prostate cancer screening rates after the 2012 US preventive services task force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol 33(22):2416–2423. https://doi.org/10.1200/jco.2015.61.6532 CrossRefPubMed

31.

Moyer VA, Force USPST (2012) Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 157(2):120–134. https://doi.org/10.7326/0003-4819-157-2-201207170-00459 CrossRefPubMed

32.

Stamey TA, Yang N, Hay AR, et al. (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317(15):909–916. https://doi.org/10.1056/nejm198710083171501 CrossRefPubMed

33.

de Boo L, Pintilie M, Yip P, et al. (2015) Time from first detectable PSA following radical prostatectomy to biochemical recurrence: a competing risk analysis. Can Urol Assoc J 9(1–2):E14–E21. https://doi.org/10.5489/cuaj.2147 CrossRefPubMedPubMedCentral

34.

Makarewicz R, Lebioda A, Terlikiewicz J, Biedka M, Wisniewski T (2009) PSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up. J Contemp Brachyther 1(2):92–96

35.

Cornford P, Bellmunt J, Bolla M, et al. (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71(4):630–642. https://doi.org/10.1016/j.eururo.2016.08.002 CrossRefPubMed

36.

Futterer JJ (2012) Imaging of recurrent prostate cancer. Radiol Clin North Am 50(6):1075–1083. https://doi.org/10.1016/j.rcl.2012.08.005 CrossRefPubMed

37.

Pucar D, Hricak H, Shukla-Dave A, et al. (2007) Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys 69(1):62–69. https://doi.org/10.1016/j.ijrobp.2007.03.065 CrossRefPubMed

38.

Alonzo F, Melodelima C, Bratan F, et al. (2016) Detection of locally radio-recurrent prostate cancer at multiparametric MRI: can dynamic contrast-enhanced imaging be omitted? Diagn Interv Imaging 97(4):433–441. https://doi.org/10.1016/j.diii.2016.01.008 CrossRefPubMed

39.

Schaefer O, Langer M (2007) Detection of recurrent rectal cancer with CT, MRI and PET/CT. Eur Radiol 17(8):2044–2054. https://doi.org/10.1007/s00330-007-0613-2 CrossRefPubMed

40.

El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7):2557–2576. https://doi.org/10.1053/j.gastro.2007.04.061 CrossRef

41.

Mazzanti R, Arena U, Tassi R (2016) Hepatocellular carcinoma: where are we? World J Exp Med 6(1):21–36. https://doi.org/10.5493/wjem.v6.i1.21 CrossRefPubMedPubMedCentral

42.

Zhao YJ, Ju Q, Li GC (2013) Tumor markers for hepatocellular carcinoma. Mol Clin Oncol 1(4):593–598. https://doi.org/10.3892/mco.2013.119 CrossRefPubMedPubMedCentral

43.

Kew M (1974) Alpha-fetoprotein in primary liver cancer and other diseases. Gut 15(10):814–821CrossRef

44.

Gupta S, Bent S, Kohlwes J (2003) Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 139(1):46–50CrossRef

45.

Trevisani F, D’Intino PE, Morselli-Labate AM, et al. (2001) Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 34(4):570–575CrossRef

46.

Saffroy R, Pham P, Reffas M, et al. (2007) New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med 45(9):1169–1179. https://doi.org/10.1515/cclm.2007.262 CrossRefPubMed

47.

Sakata J, Shirai Y, Wakai T, et al. (2008) Preoperative predictors of vascular invasion in hepatocellular carcinoma. Eur J Surg Oncol 34(8):900–905. https://doi.org/10.1016/j.ejso.2008.01.031 CrossRefPubMed

48.

Johnson PJ, Williams R (1980) Serum alpha-fetoprotein estimations and doubling time in hepatocellular carcinoma: influence of therapy and possible value in early detection. J Natl Cancer Inst 64(6):1329–1332CrossRef

49.

Vibert E, Azoulay D, Hoti E, et al. (2010) Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 10(1):129–137. https://doi.org/10.1111/j.1600-6143.2009.02750.x CrossRefPubMed

50.

Ldos SS, de Mattos AA, Zanotelli ML, et al. (2016) Alpha-fetoprotein level predicts recurrence after transplantation in hepatocellular carcinoma. Medicine (Baltimore) 95(3):e2478. https://doi.org/10.1097/md.0000000000002478 CrossRef

51.

McIntire KR, Vogel CL, Primack A, Waldmann TA, Kyalwazi SK (1976) Effect of surgical and chemotherapeutic treatment on alpha-fetoprotein levels in patients with hepatocellular carcinoma. Cancer 37(2):677–683CrossRef

52.

Bruix J, Gores GJ, Mazzaferro V (2014) Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 63(5):844–855. https://doi.org/10.1136/gutjnl-2013-306627 CrossRefPubMedPubMedCentral

53.

Llovet JM, Ricci S, Mazzaferro V, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390. https://doi.org/10.1056/NEJMoa0708857 CrossRefPubMed

54.

Oka H, Saito A, Ito K, et al. (2001) Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J Gastroenterol Hepatol 16(12):1378–1383CrossRef

55.

Bertino G, Ardiri A, Malaguarnera M, et al. (2012) Hepatocellualar carcinoma serum markers. Semin Oncol 39(4):410–433. https://doi.org/10.1053/j.seminoncol.2012.05.001 CrossRefPubMed

56.

Johnson PJ, Pirrie SJ, Cox TF, et al. (2014) The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomark Prev 23(1):144–153. https://doi.org/10.1158/1055-9965.epi-13-0870 CrossRef

57.

Zhang Q, Zeng L, Chen Y, et al. (2016) Pancreatic cancer epidemiology, detection, and management. Gastroenterol Res Pract 2016:8962321. https://doi.org/10.1155/2016/8962321 CrossRefPubMedPubMedCentral

58.

Thomas A, Dajani K, Neoptolemos JP, Ghaneh P (2010) Adjuvant therapy in pancreatic cancer. Dig Dis 28(4–5):684–692. https://doi.org/10.1159/000320099 CrossRefPubMed

59.

Ballehaninna UK, Chamberlain RS (2011) Serum CA 19-9 as a biomarker for pancreatic cancer-A comprehensive review. Indian J Surg Oncol 2(2):88–100. https://doi.org/10.1007/s13193-011-0042-1 CrossRefPubMedPubMedCentral

60.

Del Villano BC, Brennan S, Brock P, et al. (1983) Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem 29(3):549–552PubMed

61.

Poruk KE, Gay DZ, Brown K, et al. (2013) The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med 13(3):340–351PubMedPubMedCentral

62.

Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP (2004) Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol 11(7):644–649. https://doi.org/10.1245/aso.2004.11.025 CrossRefPubMed

63.

Halm U, Schumann T, Schiefke I, et al. (2000) Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 82(5):1013–1016. https://doi.org/10.1054/bjoc.1999.1035 CrossRefPubMedPubMedCentral

64.

Ferrone CR, Finkelstein DM, Thayer SP, et al. (2006) Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 24(18):2897–2902. https://doi.org/10.1200/jco.2005.05.3934 CrossRefPubMed

65.

Humphris JL, Chang DK, Johns AL, et al. (2012) The prognostic and predictive value of serum CA199 in pancreatic cancer. Ann Oncol 23(7):1713–1722. https://doi.org/10.1093/annonc/mdr561 CrossRefPubMedPubMedCentral

66.

Cramer DW (2012) The epidemiology of endometrial and ovarian cancer. Hematol Oncol Clin N Am 26(1):1–12. https://doi.org/10.1016/j.hoc.2011.10.009 CrossRef

67.

Mironov S, Akin O, Pandit-Taskar N, Hann LE (2007) Ovarian cancer. Radiol Clin N Am 45(1):149–166. https://doi.org/10.1016/j.rcl.2006.10.012 CrossRefPubMed

68.

Aggarwal P, Kehoe S (2010) Serum tumour markers in gynaecological cancers. Maturitas 67(1):46–53. https://doi.org/10.1016/j.maturitas.2010.04.017 CrossRefPubMed

69.

Duffy MJ, Bonfrer JM, Kulpa J, et al. (2005) CA125 in ovarian cancer: European Group on tumor markers guidelines for clinical use. Int J Gynecol Cancer 15(5):679–691. https://doi.org/10.1111/j.1525-1438.2005.00130.x CrossRefPubMed

70.

Soletormos G, Duffy MJ, Othman Abu Hassan S, et al. (2016) Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European group on tumor markers. Int J Gynecol Cancer 26(1):43–51. https://doi.org/10.1097/igc.0000000000000586 CrossRefPubMed

71.

Cohen JG, White M, Cruz A, Farias-Eisner R (2014) In 2014, can we do better than CA125 in the early detection of ovarian cancer? World J Biol Chem 5(3):286–300. https://doi.org/10.4331/wjbc.v5.i3.286 CrossRefPubMedPubMedCentral

72.

Buys SS, Partridge E, Black A, et al. (2011) Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA 305(22):2295–2303. https://doi.org/10.1001/jama.2011.766 CrossRefPubMed

73.

Petrucelli N, Daly MB, Feldman GL (1993) BRCA1 and BRCA2 hereditary breast and ovarian cancer. In: Pagon RA, Adam MP, Ardinger HH, et al. (eds) GeneReviews(R). Seattle: University of Washington, Seattle

74.

Lu KH, Daniels M (2013) Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention. Fam Cancer 12(2):273–277. https://doi.org/10.1007/s10689-013-9664-5 CrossRefPubMed

75.

Bast RC Jr, Xu FJ, Yu YH, et al. (1998) CA 125: the past and the future. Int J Biol Mark 13(4):179–187CrossRef

76.

Rein BJ, Gupta S, Dada R, et al. (2011) Potential markers for detection and monitoring of ovarian cancer. J Oncol 2011:475983. https://doi.org/10.1155/2011/475983 CrossRefPubMedPubMedCentral

77.

Skates SJ, Jacobs IJ, Knapp RC (2001) Tumor markers in screening for ovarian cancer. Methods Mol Med 39:61–73. https://doi.org/10.1385/1-59259-071-3:61 CrossRefPubMed

78.

Bast RC Jr, Badgwell D, Lu Z, et al. (2005) New tumor markers: CA125 and beyond. Int J Gynecol Cancer 15(Suppl 3):274–281. https://doi.org/10.1111/j.1525-1438.2005.00441.x CrossRefPubMed

79.

Bottoni P, Scatena R (2015) The role of CA 125 as tumor marker: biochemical and clinical aspects. Adv Exp Med Biol 867:229–244. https://doi.org/10.1007/978-94-017-7215-0_14 CrossRefPubMed

80.

Funt SA, Hricak H, Abu-Rustum N, et al. (2004) Role of CT in the management of recurrent ovarian cancer. AJR Am J Roentgenol 182(2):393–398. https://doi.org/10.2214/ajr.182.2.1820393 CrossRefPubMed

81.

Balestreri L, Bison L, Sorio R, et al. (2002) Abdominal recurrence of ovarian cancer: value of abdominal MR in patients with positive CA125 and negative CT. Radiol Med 104(5–6):426–436PubMed

82.

Gu P, Pan LL, Wu SQ, Sun L, Huang G (2009) CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol 71(1):164–174. https://doi.org/10.1016/j.ejrad.2008.02.019 CrossRefPubMed

83.

Bhosale P, Peungjesada S, Wei W, et al. (2010) Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. Int J Gynecol Cancer 20(6):936–944. https://doi.org/10.1111/IGC.0b013e3181e82a7f CrossRefPubMed

84.

Han LY, Karavasilis V, Hagen T, et al. (2010) Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy. Eur J Cancer 46(8):1359–1364. https://doi.org/10.1016/j.ejca.2010.02.012 CrossRefPubMed

85.

Nowak M, Janas L, Stachowiak G, Stetkiewicz T, Wilczynski JR (2015) Current clinical application of serum biomarkers to detect ovarian cancer. Prz Menopauzalny 14(4):254–259. https://doi.org/10.5114/pm.2015.55887 CrossRefPubMedPubMedCentral

86.

Anastasi E, Marchei GG, Viggiani V, et al. (2010) HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol 31(2):113–119. https://doi.org/10.1007/s13277-009-0015-y CrossRefPubMed

87.

Moore RG, McMeekin DS, Brown AK, et al. (2009) A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112(1):40–46. https://doi.org/10.1016/j.ygyno.2008.08.031 CrossRefPubMed

88.

Nolen BM, Lokshin AE (2012) Multianalyte assay systems in the differential diagnosis of ovarian cancer. Expert Opin Med Diagn 6(2):131–138. https://doi.org/10.1517/17530059.2012.661711 CrossRefPubMedPubMedCentral

89.

Bast RC Jr, Skates S, Lokshin A, Moore RG (2012) Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers. Int J Gynecol Cancer 22(Suppl 1):S5–S8. https://doi.org/10.1097/IGC.0b013e318251c97d CrossRefPubMedPubMedCentral

90.

Jacobs I, Oram D, Fairbanks J, et al. (1990) A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 97(10):922–929CrossRef

91.

Tingulstad S, Hagen B, Skjeldestad FE, et al. (1996) Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol 103(8):826–831CrossRef

92.

Timmerman D, Valentin L, Bourne TH, et al. (2000) Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the international ovarian tumor analysis (IOTA) group. Ultrasound Obstet Gynecol 16(5):500–505. https://doi.org/10.1046/j.1469-0705.2000.00287.x CrossRefPubMed

93.

Van Calster B, Van Hoorde K, Valentin L, et al. (2014) Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study. BMJ 349:g5920. https://doi.org/10.1136/bmj.g5920 CrossRefPubMedPubMedCentral

94.

Ueno T, Tanaka YO, Nagata M, et al. (2004) Spectrum of germ cell tumors: from head to toe. Radiographics 24(2):387–404. https://doi.org/10.1148/rg.242035082 CrossRefPubMed

95.

Milose JC, Filson CP, Weizer AZ, Hafez KS, Montgomery JS (2011) Role of biochemical markers in testicular cancer: diagnosis, staging, and surveillance. Open Access J Urol 4:1–8. https://doi.org/10.2147/oaju.s15063 CrossRefPubMedPubMedCentral

96.

Bosl GJ, Motzer RJ (1997) Testicular germ-cell cancer. N Engl J Med 337(4):242–253. https://doi.org/10.1056/nejm199707243370406 CrossRefPubMed

97.

Germa-Lluch JR, del Muro XG, Maroto P, et al. (2002) Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish germ-cell cancer group (GG). Eur Urol 42(6):553–562 ((discussion 562-553))CrossRef

98.

Barlow LJ, Badalato GM, McKiernan JM (2010) Serum tumor markers in the evaluation of male germ cell tumors. Nat Rev Urol 7(11):610–617. https://doi.org/10.1038/nrurol.2010.166 CrossRef

99.

Favilla V, Cimino S, Madonia M, Morgia G (2010) New advances in clinical biomarkers in testis cancer. Front Biosci (Elite Ed) 2:456–477

100.

Smith HO, Berwick M, Verschraegen CF, et al. (2006) Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol 107(5):1075–1085. https://doi.org/10.1097/01.AOG.0000216004.22588.ce CrossRefPubMed

101.

Parkinson CA, Hatcher HM, Earl HM, Ajithkumar TV (2011) Multidisciplinary management of malignant ovarian germ cell tumours. Gynecol Oncol 121(3):625–636. https://doi.org/10.1016/j.ygyno.2010.12.351 CrossRefPubMed

102.

Oronsky B, Ma PC, Morgensztern D, Carter CA (2017) Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia 19(12):991–1002. https://doi.org/10.1016/j.neo.2017.09.002 CrossRefPubMedPubMedCentral

103.

Modlin IM, Moss SF, Oberg K, et al. (2010) Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. Med J Aust 193(1):46–52PubMed

104.

Modlin IM, Gustafsson BI, Moss SF, et al. (2010) Chromogranin A—biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 17(9):2427–2443. https://doi.org/10.1245/s10434-010-1006-3 CrossRefPubMed

105.

Pulvirenti A, Rao D, McIntyre CA, et al. (2018) Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors. HPB (Oxford). https://doi.org/10.1016/j.hpb.2018.09.016 CrossRef

106.

Nolting S, Kuttner A, Lauseker M, et al. (2012) Chromogranin a as serum marker for gastroenteropancreatic neuroendocrine tumors: a single center experience and literature review. Cancers (Basel) 4(1):141–155. https://doi.org/10.3390/cancers4010141 CrossRef

107.

Frilling A, Modlin IM, Kidd M, et al. (2014) Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 15(1):e8–21. https://doi.org/10.1016/s1470-2045(13)70362-0 CrossRefPubMed

108.

Bajetta E, Ferrari L, Martinetti A, et al. (1999) Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 86(5):858–865CrossRef

109.

Wang YH, Yang QC, Lin Y, et al. (2014) Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm. Medicine (Baltimore) 93(27):e247. https://doi.org/10.1097/MD.0000000000000247 CrossRef

Title: Tumor markers: myths and facts unfolded
Authors: S. C. Faria
T. Sagebiel
M. Patnana
V. Cox
C. Viswanathan
C. Lall
A. Qayyum
P. R. Bhosale
Publication date: 01-04-2019
Publisher: Springer US
Published in: Abdominal Radiology / Issue 4/2019
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-018-1845-0

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Tumor markers: myths and facts unfolded

Abstract

Objective

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Objective

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2019

The “linguine” sign

Moustache sign

Fatty masses of the abdomen and pelvis and their complications

A comparative study of MR extracellular volume fraction measurement and two-dimensional shear-wave elastography in assessment of liver fibrosis with chronic hepatitis B

Association of advanced hepatic fibrosis and sonographic visualization score: a dual-center study using ACR US LI-RADS

The female prostate sign

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page